Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
2000 2
2001 1
2002 4
2003 7
2004 3
2005 6
2006 14
2007 14
2008 15
2009 18
2010 16
2011 16
2012 30
2013 35
2014 36
2015 27
2016 19
2017 27
2018 23
2019 29
2020 37
2021 24
2022 11
Text availability
Article attribute
Article type
Publication date

Search Results

369 results
Results by year
Filters applied: . Clear all
Page 1
Measles Virus as an Oncolytic Immunotherapy.
Engeland CE, Ungerechts G. Engeland CE, et al. Cancers (Basel). 2021 Feb 1;13(3):544. doi: 10.3390/cancers13030544. Cancers (Basel). 2021. PMID: 33535479 Free PMC article. Review.
Measles virus (MeV) preferentially replicates in malignant cells, leading to tumor lysis and priming of antitumor immunity. ...Despite challenges arising from antiviral immunity, availability of preclinical models, and GMP production, early clinical trials have demonstrate
Measles virus (MeV) preferentially replicates in malignant cells, leading to tumor lysis and priming of antitumor immunity. ...Despit
Recent advances of oncolytic virus in cancer therapy.
Mondal M, Guo J, He P, Zhou D. Mondal M, et al. Hum Vaccin Immunother. 2020 Oct 2;16(10):2389-2402. doi: 10.1080/21645515.2020.1723363. Epub 2020 Feb 20. Hum Vaccin Immunother. 2020. PMID: 32078405 Free PMC article. Review.
Oncolytic viruses have been taking the front stage in biological therapy for cancer recently. The first and most potent virus to be used in oncolytic virotherapy is human adenovirus. Recently, ongoing extensive research has suggested that other viruses like herpes s
Oncolytic viruses have been taking the front stage in biological therapy for cancer recently. The first and most potent virus to be u
Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma.
Packiriswamy N, Upreti D, Zhou Y, Khan R, Miller A, Diaz RM, Rooney CM, Dispenzieri A, Peng KW, Russell SJ. Packiriswamy N, et al. Leukemia. 2020 Dec;34(12):3310-3322. doi: 10.1038/s41375-020-0828-7. Epub 2020 Apr 23. Leukemia. 2020. PMID: 32327728 Free PMC article. Clinical Trial.
To investigate whether oncolytic virotherapy can increase immune responses to tumor antigens in human subjects, we studied T-cell responses against a panel of known myeloma TAAs using PBMC samples obtained from ten myeloma patients before and after systemic administration …
To investigate whether oncolytic virotherapy can increase immune responses to tumor antigens in human subjects, we studied T-cell res …
Mechanisms of measles virus oncolytic immunotherapy.
Pidelaserra-Martí G, Engeland CE. Pidelaserra-Martí G, et al. Cytokine Growth Factor Rev. 2020 Dec;56:28-38. doi: 10.1016/j.cytogfr.2020.07.009. Epub 2020 Jul 3. Cytokine Growth Factor Rev. 2020. PMID: 32660751 Free article. Review.
The study of measles virus (MeV) as a cancer immunotherapeutic was prompted by clinical observations of leukemia and lymphoma regressions in patients following measles virus infection in the 1970s and 1980s. Since then, numerous preclinical studies have confirmed th …
The study of measles virus (MeV) as a cancer immunotherapeutic was prompted by clinical observations of leukemia and lymphoma regress …
Oncolytic Measles Virotherapy and Opposition to Measles Vaccination.
Russell SJ, Babovic-Vuksanovic D, Bexon A, Cattaneo R, Dingli D, Dispenzieri A, Deyle DR, Federspiel MJ, Fielding A, Galanis E, Lacy MQ, Leibovich BC, Liu MC, Muñoz-Alía M, Miest TC, Molina JR, Mueller S, Okuno SH, Packiriswamy N, Peikert T, Raffel C, Van Rhee F, Ungerechts G, Young PR, Zhou Y, Peng KW. Russell SJ, et al. Mayo Clin Proc. 2019 Sep;94(9):1834-1839. doi: 10.1016/j.mayocp.2019.05.006. Epub 2019 Jun 22. Mayo Clin Proc. 2019. PMID: 31235278 Free PMC article. Review.
The purpose of this article is to address a new misinformed antivaccination argument-that measles immunity is undesirable because measles virus is protective against cancer. Having worked for many years to develop engineered measles viruses as anticancer ther …
The purpose of this article is to address a new misinformed antivaccination argument-that measles immunity is undesirable because …
Measles Vaccine.
Griffin DE. Griffin DE. Viral Immunol. 2018 Mar;31(2):86-95. doi: 10.1089/vim.2017.0143. Epub 2017 Dec 19. Viral Immunol. 2018. PMID: 29256824 Free PMC article. Review.
Measles remains an important cause of child morbidity and mortality worldwide despite the availability of a safe and efficacious vaccine. ...In addition, the safety record for the vaccine combined with advances in reverse genetics for negative strand viruses has expanded p
Measles remains an important cause of child morbidity and mortality worldwide despite the availability of a safe and efficacious vacc
Engineering and combining oncolytic measles virus for cancer therapy.
Leber MF, Neault S, Jirovec E, Barkley R, Said A, Bell JC, Ungerechts G. Leber MF, et al. Cytokine Growth Factor Rev. 2020 Dec;56:39-48. doi: 10.1016/j.cytogfr.2020.07.005. Epub 2020 Jul 3. Cytokine Growth Factor Rev. 2020. PMID: 32718830 Free PMC article. Review.
Cancer immunotherapy using tumor-selective, oncolytic viruses is an emerging therapeutic option for solid and hematologic malignancies. ...In this review, we will summarize the concepts and strategies of multi-level genetic engineering of oncolytic measles vi …
Cancer immunotherapy using tumor-selective, oncolytic viruses is an emerging therapeutic option for solid and hematologic malignancie …
Measles virus: Background and oncolytic virotherapy.
Bhattacharjee S, Yadava PK. Bhattacharjee S, et al. Biochem Biophys Rep. 2018 Jan 2;13:58-62. doi: 10.1016/j.bbrep.2017.12.004. eCollection 2018 Mar. Biochem Biophys Rep. 2018. PMID: 29326986 Free PMC article. Review.
Measles is a highly transmissible disease caused by measles virus and remains a major cause of child mortality in developing countries. ...The host cell receptors of this virus are CD46, SLAM/CD150 and PVRL4. Measles virus is latently oncotropic in nature and
Measles is a highly transmissible disease caused by measles virus and remains a major cause of child mortality in developing c
Immunomodulation in Oncolytic Measles Virotherapy.
Dietz L, Engeland CE. Dietz L, et al. Methods Mol Biol. 2020;2058:111-126. doi: 10.1007/978-1-4939-9794-7_7. Methods Mol Biol. 2020. PMID: 31486034
With the recognition of oncolytic virotherapy as an immunotherapy, the distinct interactions between oncolytic agents and the immune system have come into focus. ...The oncolytic measles virus vector platform offers manifold opportunities for tumor-tar …
With the recognition of oncolytic virotherapy as an immunotherapy, the distinct interactions between oncolytic agents and the …
Measles to the Rescue: A Review of Oncolytic Measles Virus.
Aref S, Bailey K, Fielding A. Aref S, et al. Viruses. 2016 Oct 22;8(10):294. doi: 10.3390/v8100294. Viruses. 2016. PMID: 27782084 Free PMC article. Review.
Oncolytic virotherapeutic agents are likely to become serious contenders in cancer treatment. The vaccine strain of measles virus is an agent with an impressive range of oncolytic activity in pre-clinical trials with increasing evidence of safety and efficacy
Oncolytic virotherapeutic agents are likely to become serious contenders in cancer treatment. The vaccine strain of measles vi
369 results